Impairment of Agonist-induced M Muscarinic Receptor Activation by Autoantibodies from Chagasic Patients with Cardiovascular Dysautonomia
Overview
Authors
Affiliations
Previous studies showed that circulating autoantibodies against M muscarinic receptors (anti-MR Ab) are associated with decreased cardiac parasympathetic modulation in patients with chronic Chagas disease (CD). Here we investigated whether the exposure of MR to such antibodies could impair agonist-induced receptor activation, leading to the inhibition of associated signaling pathways. Preincubation of MR-expressing HEK 293T cells with serum IgG fractions from chagasic patients with cardiovascular dysautonomia, followed by the addition of carbachol, resulted in the attenuation of agonist-induced G protein activation and arrestin-2 recruitment. These effects were not mimicked by the corresponding Fab fractions, suggesting that they occur through receptor crosslinking. IgG autoantibodies did not enhance MR/arrestin interaction or promote MR internalization, suggesting that their inhibitory effects are not likely a result of short-term receptor regulation. Rather, these immunoglobulins could function as negative allosteric modulators of acetylcholine-mediated responses, thereby contributing to the development of parasympathetic dysfunction in patients with CD.
Revealing alterations in heart rate fluctuations during the progression of Chagas disease.
Defeo M, Delaplace L, Goin J, Tersigni C, Garavaglia L, Irurzun I Front Med (Lausanne). 2024; 11:1438077.
PMID: 39318596 PMC: 11419973. DOI: 10.3389/fmed.2024.1438077.
Marin-Neto J, Rassi Jr A, Oliveira G, Correia L, Ramos Junior A, Luquetti A Arq Bras Cardiol. 2023; 120(6):e20230269.
PMID: 37377258 PMC: 10344417. DOI: 10.36660/abc.20230269.
Implications of Antimuscarinic Autoantibodies in Postural Tachycardia Syndrome.
Li H, Zhang G, Forsythe E, Okamoto L, Yu X J Cardiovasc Transl Res. 2021; 15(2):438-440.
PMID: 34409582 PMC: 8854442. DOI: 10.1007/s12265-021-10167-z.
Autoantibodies as Endogenous Modulators of GPCR Signaling.
Skiba M, Kruse A Trends Pharmacol Sci. 2020; 42(3):135-150.
PMID: 33358695 PMC: 7880908. DOI: 10.1016/j.tips.2020.11.013.